Core Insights - Travere Therapeutics reported record demand for FILSPARI in the fourth quarter, with 908 new patient starts, indicating growing physician confidence and increased adoption among both new and established prescribers [2][4][6] - The company highlighted strong revenue growth for FILSPARI, generating $103.3 million in Q4 and $322 million for the full year 2025, despite the entry of additional therapies into the market [6][17] - The FDA's review timeline for FILSPARI's supplemental indication in focal segmental glomerulosclerosis (FSGS) has been extended to April 13, 2026, due to a major amendment [6][8] Demand and Adoption - The demand for FILSPARI is attributed to its unique profile as a once-daily oral, non-immunosuppressive therapy, along with simplified monitoring requirements and alignment with KDIGO guidelines [1][4] - Adoption is particularly increasing among IgAN patients with proteinuria levels below 1.5 grams per gram, consistent with guidelines advocating for earlier intervention [1][6] Financial Performance - For Q4 2025, Travere reported U.S. net product sales of $126.6 million, with FILSPARI contributing significantly to this figure [17] - The company achieved a net income of $2.7 million in Q4 2025, a significant improvement from a net loss of $60.3 million in the same quarter the previous year [18] Research and Development - Travere has resumed global site activation for the pivotal Phase 3 HARMONY study of pegtibatinase in classical homocystinuria (HCU), with dosing expected to restart soon [5][16] - The company remains confident in FILSPARI's clinical profile for FSGS, supported by strong results from Phase 2 and Phase 3 studies [11][12] Market Outlook - Management anticipates continued growth in net product sales for FILSPARI, with gross-to-net discounts expected to increase to the mid-20% range for 2026 [20] - Operating expenses are projected to grow moderately in 2026, driven by the execution of ongoing studies and commercial investments [20]

Core Insights - Travere Therapeutics announced late-breaking data from the Phase 3 DUPLEX Study, showing that FILSPARI (sparsentan) significantly improved proteinuria outcomes in patients with focal segmental glomerulosclerosis (FSGS) compared to irbesartan [1][2][3] Study Findings - In the DUPLEX Study, 37.5% of patients treated with FILSPARI achieved a urine protein-to-creatinine ratio (UPCR) below 0.7 g/g, compared to 21.4% for those on irbesartan, indicating a relative risk (RR) of 1.8 [3] - At week 108, 19% of FILSPARI-treated patients reached the UPCR threshold versus 11.2% for irbesartan, with an RR of 1.7 [3] - Patients achieving UPCR below 0.7 g/g had a lower likelihood of reaching kidney failure (3.6% vs. 11.2%, RR 0.52) [3][4] Long-term Risk Analysis - In the DUPLEX-aligned RaDaR cohort, achieving UPCR below 0.7 g/g at 24 months was linked to a significantly lower risk of kidney failure over an additional 60 months (hazard ratio [HR] 0.14) [4] - A similar lower risk was observed for patients who achieved UPCR below 0.7 g/g at any time during the 24-month period (HR 0.27) [4] - The analysis indicated that a 26% relative reduction in UPCR for FILSPARI-treated patients correlates to a 24% reduction in the 5-year risk of kidney failure (HR 0.76) [8] Background on FSGS - FSGS is a rare kidney disorder affecting over 40,000 patients in the U.S., characterized by progressive scarring and often leading to kidney failure [7] - There are currently no FDA-approved pharmacologic therapies specifically for FSGS [7] Company Overview - Travere Therapeutics is focused on developing therapies for rare diseases, with FILSPARI currently indicated for slowing kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) [9][28]